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Introduction: Elevated midkine (MK) expression may contribute to ventricular remodeling and ameliorate cardiac
dysfunction after myocardial infarction (MI). Ex vivo modification of signaling mechanisms in mesenchymal stem
cells (MSCs) with MK overexpression may improve the efficacy of cell-based therapy. This study sought to assess the
safety and efficacy of MSCs with MK overexpression transplantation in a rat model of MI.
Methods: A pLenO-DCE vector lentivirus encoding MK was constructed and infected in MSCs. MSC migration
activity and cytoprotection was examined in hypoxia-induced H9C2 cells using transwell insert in vitro. Rats were
randomized into five groups: sham, MI plus injection of phosphate buffered saline (PBS), MSCs, MSCs-green
fluorescent protein (MSCs-GFP) and MSCs-MK, respectively. Survival rates were compared among groups using log-
rank test and left ventricular function was measured by echocardiography at baseline, 4, 8 and 12 weeks.
Results: Overexpression of MK partially prevented hypoxia-induced MSC apoptosis and exerted MSC cytoprotection
to anoxia induced H9C2 cells. The underlying mechanisms may be associated with the increased mRNA and protein
levels of vascular endothelial growth factor (VEGF), transformation growth factor-β (TGF-β), insulin-like growth factor
1 (IGF-1) and stromal cell-derived factor 1 (SDF-1a) in MSCs-MK compared with isolated MSCs and MSCs-GFP. Consistent
with the qPCR results, the culture supernatant of MSCs-MK had more SDF-1a (9.23 ng/ml), VEGF (8.34 ng/ml) and TGF-β1
(17.88 ng/ml) expression. In vivo, a greater proportion of cell survival was observed in the MSCs-MK group than in the
MSCs-GFP group. Moreover, MSCs-MK administration was related to a significant improvement of cardiac function
compared with other control groups at 12 weeks.
Conclusions: Therapies employing MSCs with MK overexpression may represent an effective treatment for improving
cardiac dysfunction and survival rate after MI.Introduction
Myocardial dysfunction after acute myocardial infarction
(MI) is a progressive condition, which is clearly associ-
ated with a poor prognosis and results in heart failure
and cardiac death [1-4]. Over the past decade, a number
of studies have documented that mesenchymal stem cell
(MSC) therapy may have a favorable impact on cardiac
function in experimental animal models or patients after* Correspondence: chmengx126@gmail.com
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reproduction in any medium, provided the orMI [5,6]. Our previous studies reported that autologous
bone marrow MSCs transplantation improved cardiac
function in 96 patients with acute MI who experienced per-
cutaneous coronary intervention and the cardioprotective
effect remained six months after the procedure [7,8].
Recently, studies from several preclinical experiments
suggested that genetic strategies may play a critical role
in improving MSC survival and differentiation [9-13].
However, insight into the mechanistic issues underlying
the effect of genetically altered MSC transplantation
remains unsettled, especially for finding a gene or a set of
genes that potentially have both autocrine and paracrine
effects in advancing MSC-directed myocardial repair.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a molecular weight of 13 kDa, first isolated as a product
of the retinoic acid-responsive gene in the embryonal
carcinoma cell differentiation system [14]. MK has various
biological activities, which promote neurite outgrowth,
the survival of embryonic neurons, and angiogenic action
[15]. In an experimental study comparing cardiac function
after ischemia/perfusion (I/R) in wild-type mice and MK-
deficient mice, there was a significant increased infarct
area and adverse left ventricular (LV) fractional shortening
(FS) in MK−/− mice [16]. Interestingly, supplemental ap-
plication of MK protein to the Mk−/− mice at the time of
I/R significantly reduced the infarcted size [16,17]. Alter-
natively, the studies from the H Takenaka and S Fukui
groups showed that MK prevented the cardiac remodeling
of mice after MI through an enhancement of angiogenesis
and subsequently improved the survival rate. Apart from
angiogenesis, additional research found that MK promo-
ted the growth of mouse embryonic stem cells by inhi-
biting apoptosis through the PI3K/Akt signaling pathway
[18]. Therefore, MK application is recently regarded as a
new therapeutic strategy for the treatment of ischemic
heart failure [19,20].
In the present study, we tested the hypothesis that the
combination of MSC transplantation and MK overex-
pression is superior to MSC transplantation in the treat-
ment of rat MI models with decreased infarct size and
improved cardiac function. LV function and angiogenesis
were separately evaluated by echocardiography and im-
munohistochemistry staining after transplantation. The
biological activities of MSCs were also examined.
Methods
Animals
Healthy female Sprague-Dawley rats (weighing 60 to
80 g for isolation of MSCs and 200 to 220 g for an MI
model) were obtained from the Vital River Laboratory
Animal Co., Ltd., Beijing Laboratory Animal Research
Center (Beijing, China); and were housed in specific
pathogen-free conditions at Nanjing First Hospital Animal
Center (Nanjing, China), in a room controlled for tem-
perature (21 ± 2°C), humidity (55 ± 5%), and light (12-h
light/dark cycle). Water was available to the rats ad libi-
tum. After acclimation for two weeks, the rats were used
for the study. All procedures involving animals were ap-
proved by the Ethics Committee for Animal Research of
Nanjing Medical University.
Isolation, culture and characterization of bone marrow
mesenchymal stem cells
Bone marrow (BM) from the femur cavity was flushed
using α-MEM medium (Invitrogen Corporation, Paisley,
UK) containing 10% FCS (Hyclone Laboratories, Perbio
Science, Cheshire, UK), 1% L-glutamine and 1% penicillin/streptomycin [21]. The cell suspension was centrifuged
(350 g, seven minutes), and cells were plated in culture
flasks (200,000 cells/cm2). Non-adherent cells were re-
moved after 72 h. MSCs were recovered based on their
capacity to strongly adhere to plastic culture dishes with-
out cell sorting. MSCs were characterized by flow cytome-
try before recombinant lentiviral vector transfection using
anti-rat CD90, CD29 FITC-conjugated antibodies and
anti-rat CD44, CD34, CD31, CD86 PE-conjugated [22].
The antibodies and isotype-matched negative control anti-
bodies labeled with FITC and PE were purchased from
BD PharMingen (San Diego, California, USA) and used in
all the experiments. Immediately before in vivo injection,
the adherent MSCs and the genetically modified MSCs
were detached with trypsin-EDTA, centrifuged for one
minute at 1,200 g, and resuspended in PBS-BSA (0.1%).
Construction of recombinant lentiviral vectors
A lentiviral vector system was selected because lentiviru-
ses exhibit limited toxicity to infected cells. To construct
the lentivirus encoding MK plasmid (pLenO-DCE-MK),
the cDNA-encoding rat MK (NM_030859, 423-bp cDNA)
was synthesized and cloned into the EcoRI and BamHI re-
striction endonuclease sites of the pLenO-DCE vector
(cat. No. 26208-1, Invabio, Shanghai, China), a mamma-
lian expression vector containing green fluorescent pro-
tein (GFP) and puromycin resistance genes. After the
correct sequence was confirmed, lentiviral vector particles
were produced in accordance with the manufacturer’s in-
structions (Invitrogen, Carlsbad, CA, USA). pRsv-REV,
pMDlg-pRRE, pMD2G and pLenO-DCE-MK (or pLenO-
DCE) were co-transfected into 293 T cells, and viral super-
natants were harvested 48 and 72 hours after transfection,
passed through 0.45-μm filters (Millipore corp., Bedford,
Massachusetts, USA) and concentrated using four rounds
of ultracentrifugation [23]. The viral pellet was resus-
pended in serum-free Dulbecco’s modified Eagle’s
medium to obtain a 10,000-fold concentrate, and the
debris was spun down. Viral stocks were stored at -80°C
until use for transduction; functional viral titers were mea-
sured using QuickTiter Lentivirus Quantitation Kit (Cell
Biolabs, San Diego, California, USA) and were deter-
mined by infection of 293 T cells [24].
Transfection of cells with lentivirus encoding rat midkine
The MSCs were transfected with pLenO-DCE-MK vec-
tors and pLenO-DCE control vectors as previously de-
scribed [25]. Briefly, primary MSCs (4 × 105 cells/well)
were seeded in six-well plates (Costar, Corning, NY, USA)
in complete culture medium. Twenty-four hours after see-
ding, MSCs were infected with recombinant lentivirus
pLenO-DCE-MK vectors in multiples of 10, 20, 50 or
100 pfu/cell (MSCs-MK). The recombinant lentivirus
encoding green fluorescent protein (pLenO-DCE) was
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bated with the virus for at least 4 h in minimal cul-
ture medium, with shaking every 15 minutes. After 4 h of
transfection, unbound virus was removed and replaced
with fresh medium. The cells were incubated for another
48 h before treatment. After determination of the effect of
infection, multiplicity of infection = 10 were chosen for
the other experiment with sufficient overexpression of
MK and minimum harm to the infected cells.
Western blot analysis
MK overexpression was confirmed by Western blot ana-
lysis as previously described [26]. The MSCs, MSCs-GFP
and MSCs-MK were lysed in lysis buffer (50 mmol/L Tris–
Cl, pH 8.0, 150 mmol/L NaCl, 0.02% NaN3, 0.1% SDS,
100mg/L phenylmethylsulfonyl Xuoride, 1mg/L aprotinin,
and 1% Triton). Lysates were centrifuged at 12,000 rpm for
15 minutes. The supernatant was collected and denatured.
Proteins were separated in 10% SDS-PAGE gels and blot-
ted onto polyvinylidene difluoride membranes (PVDF)
(Merck Millipore, Darmstadt, Germany). The blot was
blocked for 1.5 h at room temperature in 5% BSA,
followed by overnight incubation at 4°C with anti-rat MK
antibodies (Abcam, Cambridge, UK, clone # EP1143Y).
Membranes were rinsed and incubated for 1 h with the
corresponding peroxidase-conjugated secondary anti-
bodies. MK protein was detected using an enhanced
chemiluminescent reaction.
Cytoprotective effects of MK overexpression to MSCs
To determine the cytoprotective effects of MK overex-
pression for MSCs, the oxygen and glucose deprivation
(OGD) model was established in vitro [27]. After cultur-
ing for 24 h in six-well culture plates, the cell culture
media from groups of MSCs, MSCs-DCE and MSCs-MK
were replaced with glucose and serum-free Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco industries,
Oklahoma, USA). The plates were then placed in a 37°C
anoxia chamber saturated with 95% N2/5% CO2. At 12 h
after incubation, apoptosis was analyzed using a flow cyt-
ometer to detect Annexin V-PE/7AAD staining (KeyGEN
Biotech, Nanjing, China).
Analysis of MSCs for growth factors and cytokines
To determine whether MK affected the paracrine factor
secretions of MSCs, qPCR and ELISA were performed
for the mRNA and protein levels of pro-angiogenesis fac-
tors (vascular endothelial growth factor (VEGF), trans-
forming growth factor beta (TGF-β), fibroblast growth
factor (FGF)2 and FGF7) and stem cell factors (stromal
cell-derived factor (SDF)-1a, insulin-like growth factor
(IGF)-1, granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) and stem cell factor (SCF)), respectively.
Briefly, after culturing 1 × 106/ml MSCs, MSCs-GFP andMSCs-MK cells for 48 h in six-well culture plates, the cells
and the culture media were collected.
Total RNA was isolated directly from the MSCs, MSCs-
GFP and MSCs-MK using TRIzol reagent (Invitrogen Life
Technologies, Paisley, UK) and reverse-transcribed using
a Super Script III reverse transcriptase kit (Invitrogen Life
Technologies) according to standard protocols. Quantita-
tive RT-PCR analysis was performed using a SYBR Green
qPCR Master kit (Takara, Otsu, Shiga, Japan) and
300 mM primers (Table 1). After an initial 95°C (30 sec-
onds) hot start, 40 cycles of 95°C (5 seconds) and 55°C
(34 seconds) were performed using an ABI 7500 Real-
Time PCR System (Life Technologies, NY, USA).
The paracrine and secretion functions of MSCs, MSCs-
GFP and MSCs-MK cells were evaluated by measuring
the protein levels of IGF-1, SDF-1a, VEGF and TGF-β in
their culture supernatants using the ELISA kits. After a
48-hour incubation of 1 × 106/ml cells (fourth passage) in
serum-free culture medium, the media was collected and
centrifuged at 10,000 g at 4°C for five minutes, and super-
natants were stored at -20°C. Then, 100 μL of the super-
natants were assayed for IGF-1 (Genway, Canada, GWB-
ZZD062 sensitivity: <62.5 pg/ml), VEGF (Abcam, UK
ab100786, sensitivity: <0.82 pg/ml), TGF-β1 (Abcam, UK
ab119558, sensitivity: 31.3 pg/ml) and SDF-1a (Mybio-
source, USA, MBS162802) using ELISA according to the
manufacturer’s instructions.
Cytoprotective effects of MSCs on H9C2 cells
The H9C2 cell line, an embryonic rat heart-derived cell
line, was obtained from the Institute of Biochemistry
and Cell Biology, the Chinese Academy of Sciences and
maintained in DMEM supplemented with 100% v/v fetal
bovine serum and 100 mg/ml penicillin/streptomycin at
37°C in a humidified atmosphere containing 5% CO2. To
induce hypoxia, 5 × 105 H9C2 cells were planted in a
six-well Transwell co-culture plate and placed in a 37°C
anoxia chamber saturated with 95% N2/5% CO2 for eight
hours and incubated with serum free and glucose free
DMEM as described above.
To observe the impact of MK on MSCs migration and
cytoprotection, MSCs-GFP and MSCs-MK were col-
lected and seeded in the top well of a Transwell insert
(Millipore, USA) at a density of 2 × 105 cells/well in
400 μL DMEM containing 10% FCS. For inhibition ex-
periments, all MSCs were pre-incubated with CXCR4 an-
tagonist AMD3100 (10 μg/mL, Sigma-Aldrich, Shanghai,
China), the VEGFR inhibitors Sorafenib (20 nM, Selleck
Chemicals, Houston, Texas, USA) and the same concen-
tration vehicle control for 30 minutes before seeding.
The hypoxic H9C2 cells were added to the bottom wells
of the Transwell plates. DMEM containing 10% FCS was
used as a migration control. After being cultured at 37°C
in a humidified atmosphere of 5% CO2 for 12 h, the
Table 1 The primers used for qPCR assays
Genes Forward Reverse cDNA size (bp)
VEGF CAGCTATTGCCGTCCAATTGA CCAGGGCTTCATCATTGCA 131
FGF2 GGCTCTACTGCAAGAACGGC GAAACAGTATGGCCTTCTGTC 353
FGF7 TTTGGAAAGAGCGACGACTT GGCAGGATCCGTGTCAGTAT 209
TGF-β TACAGGGCTTTCGCTTCAGT TGGTTGTAGAGGGCAAGGAC 238
SDF-1a TTTCACTCTCCGTCCACCTC ATCTGAAGGGCACAGTTTGG 251
SCF TTCGCTTGTAATTGGCTTTGC TTCAACTGCCCTTGTAAGACTTGA 296
IGF-1 AAGCCTACAAAGTCAGCTCG GGTCTTGTTTCCTGCACTTC 166
GM-CSF GCTCACCCAACCCTGTCACCCG CCTCATTTCTGGACCGGCTTCC 376
β-actin AGGGAAATCGTGCGTGACAT AACCGCTCATTGCCGATAGT7 149
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tion of GFP(+) cells was determined to evaluate the
MSC migration activity, the apoptosis ratio was measured
with a flow cytometer using Annexin V-PE/7AAD staining
and the caspase-3 activity was measured by Western blot-
ting. Each assay was carried out in triplicate.
Myocardial infarction model
All animals received humane care in compliance with
the ‘Guide for the Care and Use of Laboratory Animals’
prepared by the Institute of Laboratory Animal Re-
sources, the National Research Council, and published
as the ‘Guide to the Care and Use of Experimental Ani-
mals’ by the Chinese Council on Animal Care. All pro-
cedures involving animals were approved by the Ethics
Committee for Animal Research of Nanjing Medical
University. MI was induced in 70 experimental rats by
ligating the left anterior descending (LAD) coronary ar-
tery as previously described [28], with some modifications.
Briefly, rats were anesthetized with sodium pentobarbital
(50 mg/kg intraperitoneally) and intubated and ventilated.
A left lateral thoracotomy in the fourth intercostal space
was performed to expose the anterior surface of the heart.
The proximal LAD coronary artery was ligated with a 6.0
polypropylene snare (Ethicon Inc., Somerville, New Jersey,
USA). The area displaying tissue blanching and wall mo-
tion akinesis was identified as the infarct. Rats in the sham
group underwent the same procedure except for ligation
of LAD.
Implantation of MSCs
Seventy rats were used to establish the infarcted model.
Sixty rats were selected from the 62 surviving ligated
animals, 15 of which were randomly re-selected as the
model-assessment group for baseline evaluation of the
heart infarcted size. Two weeks after the ligation, the 60
model rats were equally randomized to one of four
groups: (1) the MSCs group (n = 15), in which MSCs in
suspension were injected intramuscularly at the leftanterior free wall using a 30-gauge needle; (2) the
MSCs-GFP group (n = 15), in which the animals were
injected intramuscularly with pLenO-DCE transfected
MSCs suspension; (3) the MSCs-MK group (n = 15), in
which the animals were injected intramuscularly with
pLenO-DCE-MK transfected MSCs suspension; and (4)
the PBS group (n = 15), where the animals were injected
with PBS. PBS or cell solutions were injected at three in-
jection sites into anterior and lateral aspects of the viable
myocardium bordering the infarction (total 5.0 × 106 cells
in 0.1 mL). After injection, the chest was closed and the
animals were allowed to recover.
Echocardiography measurements
Echocardiography measurements in a blinded fashion
were performed one day before MI induction (baseline)
and 4, 8 and 12 weeks after implantation in anesthetized
rats (2% isoflurane inhalation) using a Vevo 770 cardiac
system (VisualSonics Inc., Toronto, ON, Canada). Left ven-
tricular end-diastolic diameter (LVEDD), LV end-systolic
diameter (LVESD), and LVFS were recorded from the
parasternal long-axis M-mode images using averaged
measurements from three to five consecutive cardiac
cycles in accordance with the American Society of Echo-
cardiography guidelines. Left ventricular end-diastolic and
end-systolic volumes (LVEDV and LVESV) were calcu-
lated from bidimensional long-axis parasternal views
taken through the infarcted area by means of the single-
plane area-length method [17]. The LV ejection fraction
(LVEF) was calculated as follows: LVEF = (LVEDV-LVESV)/
LVEDV) × 100%.
Histological analysis
We performed PCR to further confirm the promotion by
quantifying the mRNA expression of GFP in the LV free
wall of rat hearts. The primers of 5′-GAGCTGAAGG
GCATCGACTT-3′ and 5′-CTTGTGCCCCAGGATG
TTG-3′ were used in PCR amplification to detect GFP in
MSCs-GFP and MSCs-MK.
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mical staining with anti-CD31 antibody after cell ther-
apy, as previously described. The tissue sections (5 μm)
were stained for CD31 (Santa Cruz Biotechnology Inc.,
TX, USA) to identify capillaries. Immunohistochemical
staining was performed using a two-step immunohisto-
chemical technique with DAB (Maixin Bio, Fuzhou,
China), as described in the manufacturer’s specifications.
After being restained with hematine, the samples were
cover-slipped and photographed. The cytoplasm of the
endothelial cells was stained red. The capillaries were
counted with a × 200 microscopic objective in 10 ran-
domly selected fields in two sections per animal and av-
eraged. The criteria for being counted consisted of
having diameters of less than 50 μm and including sin-
gle or tiny vascular endothelial cells.
To detect fibrosis and apoptosis in cardiac muscle, the
hearts were excised, cut transversely, embedded in paraf-
fin, stained with Masson’s trichrome and the TUNEL kit
(Boster Bio, Wuhan, China), photographed and analyzed.
The blue area was regarded as fibrotic tissue, and the
brown area was regarded as apoptosis tissue.
Statistical analysis
Data are presented as the mean ± standard deviation.
Statistical analysis was performed using Student’s t-test
or ANOVA, as appropriate. Differences in echo param-
eter changes from baseline for each measured variable
were assessed with repeated-measures, one-way analysis
of variance (ANOVA) followed by Dunnett’s multiple-
range test to evaluate changes of the measured variable
from the corresponding baseline within the same animal.
Differences between groups in echo parameters were de-
termined by two-way ANOVA followed by Bonferroni
multiple comparison post-tests when the ANOVA indi-
cated significant differences in echo parameters. P <0.05
was considered statistically significant. All statistical
analyses were performed using SPSS 20.0 (IBM Corp.,
Armonk, NY, USA).
Results
Characterization of MSCs-MK
After three passages, the adherent MSC cells were sym-
metric with phenotypic surface antigens as reported,
including positivity for CD29, CD44 and CD90 and ne-
gativity for CD34, CD31 and CD86 (>90%, Figure S1 in
Additional file 1) [22,29,30]. We successfully developed
the high-titer lentiviral vectors that drive expression of rat
MK/GFP (pLenO-DCE-MK, 1.5 × 109 TU/ml) and GFP
(pLenO-DCE, 2.0 × 109 TU/ml) (Figures S2 and S3,
Additional file 1). After infection with recombinant
lentivirus, the efficiency of the gene transduction of
MSCs to overexpress MK was similar to that of mock
lentivirus (95.2 vs. 95.3%) (Figure 1A); moreover, abovesix phenotypic surface antigens did not change (data
not shown).
Overexpression of MK improved MSCs survival
Lentivirus-mediated transduction and expression of MK
were confirmed with real-time PCR and Western blot-
ting. Quantitative real-time PCR data indicated that
expression of MK was 54.2-fold higher in MSCs-MK
(Figure 1B). MSCs-MK also exhibited higher levels of
MK protein (Figure 1C); moreover, the midkine was
secreted (Figure 1D). To investigate the resistance of
MSCs-MK to anoxia, MSCs, MSCs-GFP and MSCs-MK
were exposed to oxygen and glucose deprivation and ana-
lyzed with the Annexin V-PE/7ADD kit. MSCs displayed
morphological changes of apoptosis and necrosis after an-
oxia. Overexpression of MK, however, partially prevented
apoptosis induced by anoxia. The numbers of apoptotic
and necrotic cells (17.9 ± 4.2%) decreased significantly in
the MSCs-MK group compared with the MSCs and
MSCs-GFP groups (28.4 ± 3.7%, p< 0.05; 32.6 ± 4.9%,
p< 0.05; Figure 1E).
MK enhanced the paracrine effects of MSCs
It is known that the main mechanisms by which MSCs
can increase repair on myocardial infarction are car-
diogenic differentiation (direct contribution), autocrine
effects (affecting the MSCs themselves) and paracrine
effects (affecting the wounded/infracted tissue) [31]. In
the present study, we did not find any evidence that MK
could promote MSC differentiation into cardiomyocytes
(data not shown). To determine whether MK impacts
the expression of pro-angiogenesis and some stem cell-
related factors, we measured mRNA of VEGF, TGF-β,
FGF2, FGF7, SDF-1a, IGF-1, GM-CSF and SCF in MSCs,
MSCs-MK and MSCs-GFP respectively (Figure 2A,B), and
the protein levels of IGF-1, SDF-1a, VEGF and TGF-β1
were also quantified by ELISA (Figure 2C). The mRNA
levels of VEGF, TGF-β, IGF-1 and SDF-1a were ele-
vated 5.85-, 2.78-, 3.7- and 2.01-fold, but no elevation
in the mRNA levels of FGF-2, FGF-7, GM-CSF and
SCF was observed in MSCs-MK compared with MSCs
and MSCs-GFP, indicating that this elevation was spe-
cific for MK overexpression. Consistent with the qPCR
results, MSCs-MK secreted more SDF-1a (9.23 ng/ml),
VEGF (8.34 ng/ml) and TGF-β1 (17.88 ng/ml) than
MSCs and MSCs-GFP; this was not the case for IGF-1
(1.89 ng/ml).
MK increased the protective effects of MSCs on
cardiomyocytes
The secreted factors of MSCs exert biological activities
by binding to their corresponding receptors on cardiac
cells. To determine the ability of MSC homing to the
Figure 1 Characterization and cytoprotective effects against anoxia of MK-transduced mesenchymal stem cells. (A) Flow cytometry
analysis of the efficiency of lentivirus affection. Black: MSCs, green: MSCs-GFP, blue: MSCs-MK two generations after lentivirus infection, red:
MSCs-MK four generations after lentivirus infection. (B) Quantitative real-time polymerase chain reaction of MK expression. (C) Western blot of MK
protein levels. (D) ELISA of MK protein levels in the culture supernatants of MSCs, MSCs-GFP and MSCs-MK. (E) Flow cytometry analysis of cell
apoptosis in all groups. MSC, mesenchymal stem cell; MSCs-MK, MSCs overexpressing midkine. The data are shown as the means ± SEM of three
independent experiments. ***p< 0.01 versus control. MSCs-GFP, Mesenchymal stem cells-green fluorescent protein; MSCs-MK, Mesenchymal
stem cells-midkine.
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cardiomyocyte viability in an ex vivo model of hypoxia,
the hypoxic H9C2 cells were co-cultured with MSCs,
MSCs-MK and MSCs-GFP in six-well Transwell plates.
Flow cytometric analysis showed that there were more
GFP+ cells in the bottom H9C2 wells in the MSCs-MK
group than the MSCs-GFP group (Figure 3A). As shown
in Figure 3A, the migratory response of MSCs-MK to
H9C2 was increased two-fold compared with MSCs-
GFP. Although both the VEGFR inhibitors (Sorafenib,
Selleck, USA) and the CXCR4 antagonist (AMD3100)
could not inhibit MSCs-MK migration, the increased
migration was blocked by a combination treatment(Figure 3A), suggesting that MK enhanced MSC mi-
gration at least partially through the VEGF/VEGFR
and SDF-1a/CXCR4 pathways.
H9C2 myoblasts were used to test the hypothesis that
paracrine factors secreted by MSCs inhibit the H9C2 cell
apoptosis induced by anoxia. The hypoxic H9C2 cells
were co-cultured with MSCs, MSCs-GFP and MSCs-
MK in six-well Transwell plates, and then, the apoptosis
rate and caspase-3 activity of H9C2 cells were ana-
lyzed. As shown in Figure 3B,C, the apoptosis ratio
and caspase-3 activity of H9C2 cells were significantly
reduced in the MSCs-MK group compared with the other
two groups (p< 0.05).
Figure 2 MK increases the paracrine effects of MSCs. A and B: Real-time PCR analysis of pro-angiogenesis factors (VEGF, TGF-β, FGF2 and
FGF7) and stem cell factor (SDF-1, IGF-1, GM-CSF and SCF) mRNAs. The relative expression of VEGF (5.85-fold), TGF-β (2.78-fold), IGF-1 (3.7-fold)
and SDF-1 (2.01-fold) mRNA in MSCs-MK were higher than in control cells (***p< 0.01). C: ELISA of IGF-1, SDF-1a, VEGF and TGF-β1 protein levels
in the culture supernatants of MSCs, MSCs-GFP and MSCs-MK. MSCs-MK secreted more SDF-1a (9.23 ng/ml), VEGF (8.34 ng/ml) and TGF-β1
(17.88 ng/ml) than MSCs (6.35, 4.75 and 9.18 ng/ml) and MSCs-GFP (6.92, 4.55 and 9.88 ng/ml); this was not the case for IGF-1 (MSCs-MK, 1.89 vs.
MSCs, 1.51 and MSCs-GFP 1.40 ng/ml). FGF, fibroblast growth factor; GM-CSF, Granulocyte-macrophage colony-stimulating factor; IGF-1,
Insulin-like growth factor 1; MSCs-GFP, Mesenchymal stem cells-green fluorescent protein; MSCs-MK, Mesenchymal stem cells-midkine; SCF, Stem cell
factor; SDF-1, Stromal cell-derived factor 1; TGF-β, Transforming growth factor beta; VEGF, Vascular endothelial growth factor.
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after MI
The effect of MK overexpression on the efficiency of
cell-based therapy with MSCs was evaluated in a rat
model of MI. Two weeks after ligation of the coronary
artery, the MI models of rat were confirmed by electro-
cardiogram, and MSCs, MSCs-GFP and MSCs-MK were
injected into the border zone myocardium. We prepared
five groups of mice, namely sham and MI plus injection
of PBS, MSCs, MSCs-GFP and MSCs-MK. All sham-
operated rats survived, whereas only 42% of the PBS-
injected MI mice survived at 12 weeks. Although there
was no significant difference in survival rate among the
MSCs (50%), MSCs-GFP (42%) and saline groups, 75%
of rats injected with MSCs-MK survived (Figure 4A).
To evaluate changes in LV dimensions and contracti-
lity, echocardiographic analyses were conducted before
the surgery and after 4, 8 and 12 weeks (Figure 4B).
In the PBS-injected MI rats, a significant increase in
LVEDD and LVESD and a significant decrease infractional shortening (%FS) were observed compared
with the sham-operated rats at four weeks and there-
after, suggesting that the LV is dilated and systolic
function is compromised. Although both LVEDD
and LVESD increased progressively in the
MSCs-, MSCs-GFP- and MSCs-MK-injected MI rats
(p< 0.05) compared with those in sham-operated Rats
at 12 weeks (Figure 4C,D), there were no significant differ-
ences (p> 0.05) among the three groups, suggesting that
injection of MSCs, MSCs-GFP and MSCs-MK retard LV
dilation but with no difference among them.
The EF and FS in the MSCs and MSCs-GFP groups
significantly and progressively decreased from four weeks
onwards, suggesting that injection of MSCs and MSCs-
GFP prevented LV dysfunction. Furthermore, the FS and
EF in the MSCs-MK-injected MI rats gradually decreased,
but these values were still significantly higher than other
groups (although only EF, p> 0.05) (Figure 4E,F). These
results suggest that injection of MSCs or MSCs-GFP alone
does not have long-term therapeutic effects, but ex vivo
Figure 3 MK increased the protective effects of MSCs on H9C2 cells. A: Flow cytometry analysis of the proportion of GFP + cells in the
bottom hypoxic H9C2 wells. B: Protective effects of MSCs, MSCs-GFP and MSCs-MK on hypoxic H9C2 cells, measured by Annexin V-PE/7AAD
staining. The graph shows the percentages of Annexin V-PE + and 7AAD + (apoptotic) cells as the means ± SEM for three independent experiments.
C: Caspase-3 activity of H9C2 was analyzed by Western blot. MSCs-GFP, Mesenchymal stem cells-green fluorescent protein; MSCs-MK,
Mesenchymal stem cells-midkine.
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effect of MSCs after MI.
MSCs-MK survived in long-term follow-up
After 12 weeks, the survival of transplanted cells was de-
termined by PCR. LV tissue from 10 mice in the MSCs-
GFP and MSCs-MK groups was used for detecting the
GFP gene by PCR. All tissues from animal groups receiv-
ing MSCs-MK were more GFP positive than MSCs-GFP,
while all tissues from the PBS and MSCs animals were
GFP negative (Figure 5A). The analysis confirmed the pre-
sence and survival of the transplanted cells and showed
that there were more surviving transplanted cells in the
MSCs-MK group than in the MSCs-GFP group.
To detect endothelial cells, the angiogenic effect was
determined using immunostaining specific for CD31 ex-
pression after the MSC therapy. There was a significant
increase in microvessel density in MSCs-GFP (64.8 ± 8.9,
p< 0.05) and MSCs-MK groups (83.7 ± 17.2, p< 0.01)
compared with the PBS group (40.3 ± 10.7), and not in
MSCs group (51.8 ± 10.3, p> 0.05). The microvessel dens-
ity in the MSCs-MK group was higher than in the MSCs
and MSCs-GFP groups (Figure 5B,C).In the present study, apoptotic cells were observed
using TUNEL stain as a marker. TUNEL-positive cells
were recognized in affected myocytic nuclei with chro-
matin condensation, and were observed in both core
and marginal zones. These cells were more common in
the PBS, MSCs and MSCs-GFP groups, whereas there
were fewer TUNEL-positive cells in the MSCs-MK group
and the cells that were present were thinly scattered in the
lesion (p< 0.05, Figure 6A,B). Masson’s trichrome staining
showed extensive myocardial fibrosis in the PBS group.
Transplantation of MSCs, MSCs-GFP and MSCs-MK at-
tenuated the development of myocardial fibrosis to differ-
ent degrees. But only the collagen volume fraction in the
MSC-MK groups was significantly smaller than in the PBS
group (p< 0.01, Figure 6C,D).
Discussion
Although MSCs are a promising source of cell basic ther-
apy (CBT) for post-MI hearts, MSCs survive poorly when
injected into the MI heart, which may limit the functional
improvement of the heart through CBT with MSCs [32].
Xing has previously reported that MK promotes self-
renewal and proliferation of human embryonic stem cells
Figure 4 Curative effect evaluation of MSCs-MK by echocardiography in rats after myocardial infarction. A: Survival rate estimated by the
Kaplan-Meier method in sham rats (sham; n = 12, none died), MI rats treated by PBS (PBS; n = 12, 7 died), MI rats treated with MSCs (MSCs; n = 12,
6 died), with MSCs-GFP (MSCs-GFP; n = 12, 7 died) and with MSCs-MK (MSCs-MK; n = 12, 3 died). Survival rates of MSCs-MK were significantly
higher than for MSCs and MSCs-GFP. B: Representative echocardiography findings in the MSCs-MK group before MI (pre-operation) and 4, 8 and
12 weeks after MI (post-treatment). C, D, E and F: Measurements were performed at baseline before MI and 4, 8 and 12 weeks after MI, as
indicated. (C) Left ventricular end-diastolic diameter (LVEDD). (D) Left ventricular end-systolic diameter (LVESD). (E) Fractional shortening (FS).
(F) Ejection fraction (EF). *indicates p< 0.05 vs. the PBS group at the same time-point, one-way ANOVA. All values represent mean ± SEM. MI,
Myocardial infarction; MSCs-GFP, Mesenchymal stem cells-green fluorescent protein; MSCs-MK, Mesenchymal stem cells-midkine.
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progression toward the S phase and that MK enhan-
ces mouse embryonic stem cells (mESCs) self-renewal
through the PI3K/Akt signaling pathway [33]. Further-
more, exogenous MK has a protective effect in models of
MI of mice and rats. In this present study, we show that
ex vivo up-regulation of MK in MSCs significantlyincreases both survival rate and paracrine signaling of the
MSCs after injection into the MI heart, thereby signifi-
cantly enhancing the efficiency of the CBT.
Lentiviruses are promising vectors for delivery of MK
transgenes due to their ability to integrate and transduce
both dividing and non-dividing cells, which are less con-
strained by the size of the MK transgene and facilitate
Figure 5 Histological analysis 12 weeks after therapy. A: The GFP signal of transplanted cells was determined by PCR (A). B and C:
CD31-positive capillaries in the peri-infarct zone. C, Histogram of data shown in D. All values represent mean ± SEM. * p< 0.05 vs. PBS group.
The capillary density in the MSCs-MK group was significantly greater than that of the PBS group. GFP, Green fluorescent protein; MSCs-MK,
Mesenchymal stem cells-midkine.
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analysis in this study revealed that there was no signifi-
cant difference in the MSC surface markers (positive for
CD29, CD44 and CD90 and negative for CD34, CD86 and
CD31) before and after the pLenO-DCE vector lentivirusFigure 6 Representative histology pictures of postmortem apoptosis
by the TUNEL apoptosis detection kit. C. and D. Photomicrographs of repre
Myocardium (red) was replaced by fibrous tissue (blue) in all groups in diff
PBS group.infection that was carried with the GFP +maker, and most
MSCs remained stable and undifferentiated after lenti-
virus infection, suggesting that the infection of MSCs
with the pLenO-DCE lentiviral vector did not affect the
MSCs and that MSCs infected with the pLenO-DCEand fibrosis. A. and B. Apoptosis in the heart tissue as revealed
sentative myocardial sections stained with Masson’s trichrome.
erent degrees. Data are shown as means ± SEM. *p< 0.05, ***p< 0.01 vs.
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therapy. Thus, our results revealed that a lentivirus titer
of 1.5 to 2.0 × 109 TU/ml is promising and adequate for
infecting MSCs.
One of the significant challenges in the clinical appli-
cation of MSCs is the fact that the survival of injected
cells is very low in vivo, especially in the post-MI heart.
Our results show that overexpression of MK in MSCs
could prevent the ex vivo apoptosis phenomenon in-
duced by oxygen and glucose deprivation, and continued
survival of the injected MSCs in the MI heart at 12 weeks
was observed only when the MSCs overexpressed MK,
suggesting that MK may enhance the survival of MSCs.
The autocrine and paracrine factors whose production
is modulated by MK may also be involved in the en-
hanced survival and protective effects on cardiomyo-
cytes of MK-MSCs. Up-regulation of paracrine factors
plays an important role in mediating the beneficial ef-
fects of CBT with MSCs. Using qPCR and ELISA ana-
lyses, we have identified several growth factors/
cytokines, including VEGF, TGF-β and SDF-1a, that are
up-regulated in the MSCs-MK cell and its culture sub-
strate. When co-cultured with hypoxic H9C2 cells,
overexpression of MK promoted MSCs migration, in
part, through the VEGF/VEGFR and SDF-1a/CXCR4
pathways and prevented H9C2 apoptosis by reducing
caspase-3 activity. However, these changes are not sta-
tistically significant relative to those factors in serum of
MI model rats that were treated with MK-MSCs, pos-
sibly partly because of individual differences of animals
and the factors binding to their receptors.
MK is associated with cancer and serves as both bio-
marker and therapeutic target. Thus, we have assessed
engineered MSC proliferation by CCK8 kits, cell cycle by
flow cytometry and telomerase reverse transcriptase
(TERT) by Q-PCR. There was no difference among the
control cells and MSCs-MK in the cell cycle and the rela-
tive expression levels TERT mRNA, but MSCs-MK cells
have more potent proliferative capacity than the control
MSCs and MSCs-GFP cells. The results showed that
MSCs-MK had no tumorigenic effects (Figures S4, S5 and
S6 in Additional file 1).
Although injection of either MSCs or MSCs-GFP into the
MI hearts slightly but not significantly prevented LV dilation
and expansion of MI, it failed to improve LV systolic
function, LV remodeling or survival of the animals. However,
injection of MSCs-MK remarkably improved these parame-
ters, indicating that MK enhances the efficiency of CBT
with MSCs. Because both lentiviral-mediated transduction
and stable expression of MK in MSCs improved the effi-
ciency of CBT, the effect of MK is independent of lenti-
viral transduction. Thus, our results clearly suggest that
ex vivo modification of signaling molecules, such as MK,
can improve the therapeutic potential of MSCs.Limitations
The current study has several limitations. First, the func-
tional assay of cord formation by hUVEC was not po-
sitive, which may be due to experimental design or test
operation. Second, echo evaluation should be performed
after MI to avoid potential variability among the animals.
On the other hand, we have randomized MI rats into
groups after operation, which also eliminated the stress
effect to the MI-model rats during the echocardiography
detection. Third, the in vitro study should be conducted
in the neonatal rat cardiomyocytes rather than H9C2 cell
line, though this has been validated as a useful model for
studying oxidative stress and cardiomyocyte apoptosis.
Finally, the in vivo imaging detection of GFP fluores-
cence signals showed that the fluorescence intensity of
GFP presented individual difference in groups of MSCs-
MK and MSCs-GFP which might be associated with a
high degree of model-to-model variability, along with
potential variability in sensitivity difference of the detec-
tion system.Conclusions
In summary, our study suggests that MSCs overexpressing
MK transplantation stimulated vasculogenesis effectively
via the increase of pro-angiogenesis factors (VEGF, TGF-β),
partially prevented hypoxia-induced MSC apoptosis and
exerted MSC cytoprotection to anoxia-induced H9C2
cells. For these reasons, this combined strategy of cell
transplantation with MK therapy should prove to be a
useful approach in the treatment of MI.Additional file
Additional file 1: This additional file is composed of six figures as
follows: Figure S1. Flow cytometric analysis of MSCs for CD29, CD44,
CD90, CD34, CD31 and CD86 expression. A total of 10,000 events were
scored. Results are expressed as the percentage of positive cells in the
whole population on representative histogram plots. Figure S2.
Recombinant lentiviral vectors were digested by restriction enzymes. M,
DNA maker; 1, pLenO-DCE-MDK; 2, pLenO-DCE. Arrow shows the MK gene
(421 bp). Figure S3. 293 T cells were infected with 0.01 μL pLenO-DEC and
pLenO-DCE-MK lentivirus, and the ratio of positive cells were analyzed by
flow cytometry. Titer (293 T-transducing units/ml) = 100,000 (target cells) ×
(% of RFP-positive cells/100)/volume of supernatant (in ml), PLenO-DCE-MK:
1.5 × 109 TU/ml and PLeno-DCE-GFP: 2.0 × 109 TU/ml. Figure S4. The Cell
Counting Kit-8 (CCK8 kit) was used to monitor cell proliferation. The MSC,
MSC-GFP and MSC-MK cells were plated at a density of 5,000 cells/well in
96-well plates. After 24 and 48 hours, 10 μL CCK-8 was added to each well.
Absorbance was detected with an enzyme calibrator at 570 nm and then
optical density (OD) values were measured. Two batches MSCs-MK cells
both have more potent proliferative capacity than the control MSCs and
MSCs-GFP cells. Figure S5. Analysis of cell cycle distribution was performed
by flow cytometry. Representative cell cycle histograms of MSC, MSC-GFP
and MSC-MK were shown in this figure. All data of substantial accumulation
of cells in G1, G2 and S phase were analyzed, and there was no difference
among the control cells and the MSCs-MK. Figure S6. Real-time PCR
analysis of telomerase reverse transcriptase (TERT) mRNAs, and there was no
difference among the control cells and the MSCs-MK.
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